Lv41
490 积分 2024-08-13 加入
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
2个月前
已完结
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
3个月前
已完结
An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy
6个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
10个月前
已完结
PSMA and Sigma-1 receptor dual-targeted peptide mediates superior radionuclide imaging and therapy of prostate cancer
10个月前
已完结
ABBV-319: A CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies
11个月前
已完结
ABBV-319: A CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies
11个月前
已关闭
Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma
11个月前
已完结
TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers
1年前
已完结
皖公网安备34019202002308
